Vet Pathol Download to Citation Manager
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Affolter, V. K.
Right arrow Articles by Moore, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Affolter, V. K.
Right arrow Articles by Moore, P. F.
Vet Pathol 39:74-83 (2002)
© 2002 American College of Veterinary Pathologists

Localized and Disseminated Histiocytic Sarcoma of Dendritic Cell Origin in Dogs

V. K. Affolter and P. F. Moore

Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University California, Davis, CA


   Abstract
Top
 Abstract
Material and Methods
 Results
 Discussion
 References
 
Canine histiocytic proliferative disorders include a wide spectrum of diseases characterized by different biologic behaviors. The etiology and pathogenesis of these diseases are largely unknown. The clinicopathologic, morphologic and immunophenotypic characteristics of canine localized and disseminated histiocytic sarcoma were examined in 39 dogs. Rottweilers, Bernese Mountain Dogs, and retrievers were most commonly affected (79%). Localized histiocytic sarcomas (19 dogs) arose from a single site, and metastatic lesions were observed in draining lymph nodes. Predilection sites were subcutis and underlying tissues on extremities, but tumors occurred in other locations, including spleen, lung, brain, nasal cavity, and bone marrow. Disseminated histiocytic sarcomas (20 dogs), a multisystem disease previously described as malignant histiocytosis, primarily affected spleen, lungs, bone marrow, liver, and lymph nodes. Both localized and disseminated canine histiocytic sarcomas were composed of pleomorphic tumor cell populations. CD1+, CD4-, CD11c+, CD11d-, MHC II+, ICAM-1+, Thy-1± tumor cells were identified in all snap-frozen samples (31 dogs). This phenotype is characteristic for myeloid dendritic antigen-presenting cell lineage. Hence, canine localized and disseminated histiocytic sarcomas are likely myeloid dendritic cell sarcomas. Dendritic antigen-presenting cells are a heterogeneous cell population with regards to their ontogeny, phenotype, function, and localization. The exact sublineage of the proliferating dendritic antigen-presenting cells involved in canine histiocytic sarcomas remains to be determined. Phenotypic analysis of formalin-fixed tissues from eight dogs was limited by available markers. Morphologic features and the phenotype CD18+, CD3-, and CD79a- were the most useful criteria to indicate likely histiocytic origin.

Key words: CD1; CD11c; dendritic antigen-presenting cells; dogs; histiocytic sarcoma; histopathology; ICAM-1; immunohistochermistry; malignant histiocytosis; MHC II.

Previous reports of canine proliferative histiocytic diseases have documented a range of disorders with marked differences in clinical behavior and pathologic features. These disorders include cutaneous histiocytoma, reactive histiocytosis (cutaneous or systemic form), and malignant histiocytosis.1,22,26,30,32,33,39,47 Canine cutaneous histiocytoma is a mostly benign epitheliotropic neoplasm composed of intraepidermal dendritic antigen-presenting cells (APC) also called Langerhans cells.15,22,33 Most canine cutaneous histiocytomas spontaneously regress. Their clinical and pathologic features resemble those of some forms of Langerhans cell histiocytosis (LCH) in humans.11,13,45 Canine reactive histiocytosis is either limited to the skin (cutaneous histiocytosis) or simultaneously affects skin and other organ systems (systemic histiocytosis).1,26,30,41,46 Skin lesions are characterized by an angiocentric pleocellular infiltrate composed of activated interstitial myeloid perivascular dendritic APC of the dermis, lymphocytes, and neutrophils.1 The clinical course and response to immunosuppressive therapy are consistent with a reactive process, which likely arises in the context of immune system dysregulation.1

Canine histiocytic neoplasia occurs as a localized tumor or a disseminated neoplastic process.14,17,19,23,32,39 Localized histiocytic sarcomas develop from a single site. They are locally invasive and metastasize to draining lymph nodes. The majority arise in the subcutis, but other primary locations have been observed.17 Disseminated canine histiocytic sarcoma was first described as malignant histiocytosis of Bernese Mountain Dogs.32,37,39 However, this condition since has been documented in other breeds.18,23,35,43,44,57,60 Disseminated histiocytic sarcoma is an aggressive multisystem disease characterized by presence of multiple tumor masses in several organ systems. Primary sites are spleen, lung, and bone marrow. Secondary lesions are observed in lymph nodes and liver, and subsequently other organs can be affected. The cellular origin of canine histiocytic sarcomas is largely unknown. Malignant histiocytic proliferations have been documented best in humans and include histiocytic sarcomas and Langerhans cell histiocytosis.3,11,45 Histiocytic sarcomas in humans are of either macrophage origin or myeloid dendritic APC origin.3,11,45

The goal of this study was to document morphologic and phenotypic characteristics of canine localized histiocytic sarcoma (19 dogs) and canine disseminated histiocytic sarcoma (20 dogs). Canine histiocytic sarcomas are composed of a pleomorphic proliferation of myeloid dendritic APC and hence resemble dendritic cell sarcomas described in humans.11,45


   Material and Methods
Top
 Abstract
 Material and Methods
Results
 Discussion
 References
 
Tissue handling

Tissue samples from 39 dogs included needle biopsies, punch and excisional biopsies, bone marrow smears, or postmortem tissues. The samples were submitted by veterinary practitioners, the Veterinary Medicine Teaching Hospital at the University of California at Davis, or other veterinary schools throughout the United States. Fresh tissue samples (31/39) were bisected, and one half was fixed in 10% neutral buffered formalin and embedded in paraffin. The other half was embedded in OCT compound (Finetek, Sakura USA, Torrance, CA) and snap frozen in isopentane cooled to the point of freezing in liquid nitrogen. Normal canine control tissues for immunohistochemistry (skin, tongue, spleen, thymus) were handled identically. The remaining tissue samples (8/39) were submitted in formalin only.

Classification

Morphologic features were evaluated on 4–6-µm, hematoxylin and eosin (HE)-stained sections of formalin-fixed, paraffin-embedded tissue. The presumptive diagnosis of a histiocytic neoplasm was based on morphologic features previously described.18,23,32 According to the criteria used for humans, the cases were categorized as localized or disseminated histiocytic sarcomas.11,45

Antibodies

A panel of leukocyte-specific antibodies (Table 1), previously used for characterization of canine cutaneous histiocytomas and canine reactive histiocytosis, was used in this study.1,33 The sources and reactivity of these antibodies were fully documented previously.31 Cryosections (6 µm) from 31 dogs were evaluated with the entire panel of antibodies (Table 1). A limited number of antibodies recognize formalin-fixed epitopes (Table 1). These antibodies can detect expression of CD3{epsilon}, CD11d ({alpha}D), CD18, CD45RA, and CD79a in formalin-fixed, paraffin-embedded tissues. These reagents were used for evaluation of eight dogs where only formalin-fixed, paraffin-embedded tissues were available.


View this table:
[in this window]
[in a new window]
  		Table 1. Monoclonal antibodies specific for canine leukocyte antigens.31

 
Immunohistochemistry

Cryosections were fixed in acetone (3 minutes), and endogenous peroxidase was quenched by immersing slides in hydrogen peroxide (0.3%), sodium azide (0.1%), and phosphate-buffered saline (PBS) for 10 minutes. Following a blocking step with 10% heat inactivated horse serum in PBS (20 minutes), the dog-specific monoclonal antibodies were applied to the sections for 30 minutes. Appropriate antibody dilutions, prepared in 10% horse serum in PBS, were determined by previous titration of each antibody on frozen sections of normal canine spleen. If available, skin samples from each dog were used as control tissue for the expression of the CD1a allotype by the intraepidermal Langerhans cells recognized by CA9.AG5 (Table 1). Omission of the primary antibody or application of an isotype-matched nonspecific antibody was used as a negative control in each run. Secondary biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) was applied to each section for 30 minutes followed by streptavidin–horseradish–peroxidase (Zymed, South San Francisco, CA) for 20 minutes according to instructions of the manufacturers. Between each step, the sections were washed thoroughly in PBS. Amino-9-ethyl-carbazole (AEC; Sigma Chemical Co., St. Louis, MO) was used as the chromogen. The tissue sections were counterstained with hematoxylin (Gill's formula 3; Fischer, Pittsburgh, WA), air dried, and coverslipped.

Eight tissue samples were submitted in formalin only. Immunohistochemical phenotyping was performed on 6-µm paraffin-embedded sections. The sections were deparaffinized in xylene and hydrated through graded ethanol solutions. Several antigen retrieval procedures to unmask antigen epitopes were evaluated, including enzymatic digestion with trypsin (0.1% trypsin and 0.1% CaCl2) for 20 minutes at 37C) or microwaving (19 minutes) or steaming (30 minutes) of tissue sections immersed in 10 mM citrate, pH 6 (Dako, Carpinteria, CA).48 The best results were achieved with steaming of the tissue sections in citrate buffer. Formalin-fixed tissue sections of all eight dogs were therefore steamed previous to the blocking step with 10% heat inactivated horse serum in PBS. The tissue sections were subsequently stained as described above.


   Results
Top
 Abstract
 Material and Methods
 Results
Discussion
 References
 
Clinical summary and distribution of lesions

Histiocytic sarcomas were observed in a variety of breeds (Table 2), but Rottweilers, Bernese Mountain Dogs, and retrievers were highly represented (79%). The ages of affected dogs ranged from 2 to 13 years, and a female:male ratio of 1.2:1 was observed. Localized histiocytic sarcoma was diagnosed in 19 dogs, and disseminated histiocytic sarcomas were seen in 20 dogs. Frequency of tissue involvement with localized histiocytic sarcoma and disseminated histiocytic sarcoma are listed in Table 3. The majority of localized histiocytic sarcomas were observed in the subcutis (13/19), whereas most disseminated histiocytic sarcomas presented with widespread lesions in several internal organ systems, and subcutaneous masses were seen in only seven dogs (Table 3).


View this table:
[in this window]
[in a new window]
  		Table 2. Dog breeds affected with localized (LHS) and disseminated (DHS) histiocytic sarcoma.

 

View this table:
[in this window]
[in a new window]
  		Table 3. Frequency of tissue involvement in 19 dogs with localized histiocytic sarcoma (LHS) and 20 dogs with disseminated histiocytic sarcoma (DHS).

 
All except one of the subcutaneous localized histiocytic sarcomas were located on limbs. One dog presented with a mass on the chest. The tumor masses often invaded the deep dermis and underlying skeletal muscles and fascia. The remaining six localized histiocytic sarcomas (Table 3) affected the spleen, the tongue, a lung lobe, the brain stem, the nasal cavity, and a vertebral bone and epidural space (Fig. 1). For five dogs, samples from enlarged draining lymph nodes were submitted together with the primary tumor. Metastases were present in three lymph nodes, and two lymph node samples had no evidence of neoplasia. The localized histiocytic sarcoma in the spleen was associated with numerous liver metastases.



View larger version (56K):
[in this window]
[in a new window]
  		Fig. 1. Vertebral column and spinal cord; sagittal section; Rottweiler, dog No. 19. A nonencapsulated, white homogeneous mass originates from the dorsal portion of the vertebral body. The mass protrudes into the vertebral canal and exerts compression on the spinal cord. Bar = 2 cm.
Fig. 2. Spleen; Bernese Mountain Dog with disseminated histiocytic sarcoma, dog No. 29. The spleen is markedly enlarged and contains numerous white, nonencapsulated, and often coalescing nodules. The nodules range in size from a few millimeters to 2 cm in diameter. Bar = 2 cm.

 
Disseminated histiocytic sarcomas were most often found in the spleen (Fig. 2), liver, lung, bone marrow, and lymph nodes (Table 3). Additional lesions were noted in many different organ systems (Table 3). The majority of dogs had a history of nonspecific initial clinical signs, which included anorexia, lethargy, weakness, and weight loss, and clinical evaluation revealed involvement of several organ systems at the time of presentation. Additional clinical signs varied. Dogs with pulmonary masses and neoplastic involvement of the hilar lymph nodes presented with dyspnea. Lameness was observed in dogs with extensive proliferative bone marrow lesions associated with destruction of surrounding bone. Intravertebral lesions were seen in only two Rottweilers; both dogs presented with ataxia and hind leg paresis and paralysis.

Clinical follow-up revealed a more favorable outcome for dogs with localized histiocytic sarcomas than for dogs with disseminated lesions. Wide surgical excisions or amputation in dogs with large masses on extremities were performed in all 13 dogs with subcutaneous sarcomas. No postsurgical recurrence or metastasis was reported in 5/13 dogs. The remaining eight dogs were lost to further clinical follow-up. Radiotherapy was used successfully to treat a histiocytic sarcoma in the tongue, and no subsequent recurrence was reported. Of four dogs with internal localized histiocytic sarcomas, two were euthanatized shortly after the diagnosis was established and for two others submitted tissues had been collected upon necropsy. One dog was lost to clinical follow-up.

Clinical outcome in dogs with disseminated histiocytic sarcomas reflected the very aggressive behavior and poor prognosis of this disease. Fast deterioration and lack of response to chemotherapy was seen in seven dogs. One dog died spontaneously, and the other 6 dogs were euthanatized upon the owners' requests. Necropsies to evaluate the extent of the disease were performed on five of these dogs. Another seven dogs were in very poor general condition at the time of presentation. These dogs were euthanatized, and tissue samples for histology and immunophenotyping were collected upon necropsy. No clinical follow-up was available for six dogs.

Morphologic features

Localized and disseminated histiocytic sarcomas were characterized by identical morphologic features. Poorly demarcated, locally invasive tumor masses were composed of a dense pleomorphic cell proliferation, which effaced normal tissue architecture. There were multiple areas of necrosis. Morphology and arrangement of the tumor cell population varied among nodules and among different areas within a lesion (Figs. 3, 4). Some tumor nodules were composed of individualized large round cells with abundant amphophilic cytoplasm. Occasional cytoplasmic vacuolization was observed. A second pattern was characterized by variably dense proliferations of plump spindle cells with long cytoplasmic processes. Often both cell types were present within one lesion. Neoplastic multinucleated giant cells were common and presented as either large round cells or as bizarre stellate cells with long cytoplasmic processes (Fig. 3). There was marked anisokaryosis (Figs. 3). Large vesicular nuclei were round to oval or indented and twisted and contained one or several nucleoli; other nuclei were slightly smaller, round or elongated, and characterized by more condensed, coarse chromatin (Figs. 3, 4). The mitotic rate varied and ranged from one to seven mitosis per high power field (40x objective). Phagocytosis by the tumor cells was occasionally seen. The phagocytic vacuoles contained neutrophils or cellular fragments. The extent of a reactive leukocytic infiltrate varied among dogs and ranged from a few dispersed cells to a prominent reactive infiltrate. Neutrophils were consistently observed. The number of small lymphocytes ranged from occasional dispersed cells to aggregates.



View larger version (89K):
[in this window]
[in a new window]
  		Fig. 3. Lung, histiocytic sarcoma; Bernese Mountain Dog, dog No. 15. The pleomorphic tumor cell population consists of spindle cells, individualized round cells, and multinucleated giant cells. There is marked anisokaryosis. Admixed are scattered reactive small lymphocytic. HE. Bar = 30 µm.
Fig. 4. Subcutaneous tissue, histiocytic sarcoma; Golden Retriever, dog No. 11. The tumor is composed of plump spindle cells arranged in loose bundles. Admixed are occasional round tumor cells. The tumor cells have round to oval nuclei, mostly characterized by condensed chromatin. A few round vesicular nuclei with more prominent nucleoli are present; occasional karyorrhexis is also present. HE. Bar = 30µm.

 
Immunohistochemistry

Despite their variable morphology, the tumor cells expressed a consistent phenotype. Moreover, no differences in the phenotype was noted between localized and disseminated histiocytic sarcomas. Based on the expression of the leukocyte antigens CD45 and CD11a/CD18, all 39 sarcomas were of leukocytic origin (Table 4). Tumor cells in snap-frozen tissues of 31 dogs consistently expressed molecules involved in antigen presentation, including CD1b, CD1c (Fig. 5), and major histocompatibility complex (MHC) class II. In carriers of the CD1a allotype recognized by CA9.AG5, coexpression of CD1a was seen (Table 4). The tumor cell populations expressed the ß2-integrin adhesion molecule CD11c (Fig. 6) and the intercellular adhesion molecule ICAM-1. With consistent expression of CD1, CD11c, MHC class II, and ICAM-1, the tumor cells therefore displayed a phenotype characteristic of myeloid dendritic APC origin.5,29,33 The tumor cells were consistently negative for CD4, which is upregulated upon activation of dendritic APC, as seen in canine reactive histiocytosis.1 Additional surface proteins were identified on these tumor cells; however, they did not contribute to further differentiation of the tumor cell population. These surface molecules are either broadly expressed by leukocytes, such as CD44, or they were inconsistently expressed by the tumor cells, such as CD45RA or the adhesion molecules CD11b, CD49d, and ICAM-3 (Table 4). The majority of tumor tissues lacked expression of CD90 (Thy-1); its expression was limited to a perivascular subpopulation of tumor cells in a few cases (Table 4). Reactive lymphocytic infiltrates consisted mainly of CD8+, TCR{alpha}ß+ T cells. CD21+ B lymphocytes were less common and occurred as small aggregates. CD4+ T cells and TCR{gamma}{delta} T cells were rare.


View this table:
[in this window]
[in a new window]
  		Table 4. Phenotype of dendritic APC in localized and disseminated histiocytic sarcomas evaluated from frozen (n = 31) or formalin-fixed (n = 8) canine tissues.

 


View larger version (94K):
[in this window]
[in a new window]
  		Fig. 5. Spleen; histiocytic sarcoma; Labrador Retriever, dog No. 20. The cytoplasmic membranes of the tumor cells stain positive for dog-specific CD1 antibody. Cryosection, immunhostochemistry with CA13.9H11, AEC. Bar = 30 µm.
Fig. 6. Spleen; histiocytic sarcoma; Labrador Retriever, dog No. 20. The cytoplasmic membranes of the tumor cells also stain positive for dog-specific CD11c antibody. Cryosection, immunhostochemistry with CA11.6A1, AEC. Bar = 30 µm.

 
Limited conclusions could be drawn from immunohistochemical results for formalin-fixed, paraffin-embedded tissues from eight dogs. The histiocytes consistently expressed CD18, and those from two dogs expressed CD45RA. The tumor cell populations in all samples were negative for CD3{epsilon} and CD79a, two surface molecules used to identify lymphocytes of T- or B-cell origin. A dispersed population of reactive small CD3{epsilon}+ lymphocytes was present in all cases; the number of reactive lymphocytes, however, varied among different tissue samples.


   Discussion
Top
 Abstract
 Material and Methods
 Results
 Discussion
References
 
In this investigation, we documented that canine histiocytic sarcomas are proliferations of myeloid dendritic APC displaying a CD1+, CD11c+, MHC class II+, ICAM-1+ phenotype. CD1 is consistently expressed by dendritic cells in the thymic medulla, the epidermis and mucosal epithelia, the dermis, and other tissues in humans and dogs.5,12,29,31,33,36,49,59 Coexpression of CD1 and high levels of MHC class II antigens, both involved with antigen presentation, are characteristic for professional APC.5,29,31,36 Adhesion molecules are variably expressed by different leukocyte subpopulations. The ß2-integrin CD11c and the ICAM-1, which are consistently present on canine myeloid dendritic APC,33 were strongly expressed by these tumor cells, whereas expression of other adhesion molecules such as CD11b, CD49d, and ICAM-3 was variable (Table 4). These observations confirm the myeloid dendritic cell origin of these tumor cells.

Myeloid dendritic APC themselves are a heterogeneous population of cells in terms of their ontogeny, phenotype, function, and localization34,49 (Fig. 7). Together with macrophages, they evolve from a common CD34+ progenitor cell in the bone marrow (Fig. 7). Various stem cell factors and cytokines (Fig. 7) induce differentiation into either macrophages or myeloid dendritic cells.6–8,40,49,54,55 Under the influence of granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor {alpha} (TNF-{alpha}), and interleukin (IL)-4, CD34+ precursors differentiate into CLA+ (cutaneous lymphocyte-associated antigen) intraepithelial dendritic APC, called Langerhans cells or CLA- interstitial dendritic cells. Langerhans cells reside in the epidermis, follicular epithelium, and mucosal epithelia, and interstitial dendritic APC are present in various nonlymphoid tissues, e.g., as perivascular dermal dendritic APC.5,9,29,33,34,36,49,59 As professional APC, myeloid dendritic cells are involved in the immune surveillance of their environment.49 After antigen uptake, Langerhans cells and interstitial dendritic cells migrate to the lymphoid tissue. As interdigitating cells, they present processed antigens in context with MCH class I, MHC class II molecules or CD1 to lymphocytes and hence induce an immune response.5,36,53 A third subset of myeloid dendritic APC has been documented in humans.34,49 They develop from a CD34+ bone marrow precursor subset that expresses high levels of IL-3{alpha} receptors (IL-3R{alpha}) (Fig. 7). At an undifferentiated stage and independently of inflammatory stimuli or previous uptake and processing of foreign antigens, IL-3R{alpha}high, CD45RA+, CD4+ dendritic cells migrate from the bone marrow directly into T-cell dependent areas of lymphoid tissues.34,49 In vitro studies have shown that upon maturation these dendritic cells become potent APC.34



View larger version (32K):
[in this window]
[in a new window]
  		Fig. 7. Ontogeny and phenotypic characteristics of myeloid dendritic antigen-presenting cells.29,34 216,49,59 DC = dendritic cells; BG = Birbeck's granules.

 
Proliferative diseases of dendritic APC have been well documented in humans. A large group of diseases with biologically variable behavior are categorized as LCH.3,11 True malignant histiocytic proliferations are rare and may consist of macrophages or dendritic APC.4,11,16 Disseminated forms of histiocytic sarcoma may mimic other malignancies such as anaplastic large cell lymphoma.4,16,42 Localized histiocytic sarcomas often have been referred to as malignant fibrous histiocytomas.21,28,50,58 Immunophenotyping is therefore essential to confirm the diagnosis.4,11,16,42,61 S100, lysozyme, {alpha}1-antitrypsin, {alpha}1-antichymotrypsin, soya bean agglutinin, and peanut agglutinin have previously been used to diagnose the histiocytic origin of round cell and spindle cell sarcomas in humans.10,13,38,42,51 However, CD1, CD11b, CD11c, CD14, CD68, and MHC class II are considered the most reliable markers for identifying histiocytic origin and differentiating between dendritic cell origin (CD1+, CD11c+) and macrophage origin (CD11b+, CD14+, CD68+).10,20,24,42,51

Proliferative diseases of different dendritic APC subpopulations have recently been documented in dogs. Canine cutaneous histiocytoma, a mostly benign self-limiting cutaneous epitheliotropic neoplasm, is composed of a proliferation of CD1+, CD11c+, Thy-1-, CD4- canine Langerhans cells.33 Canine cutaneous histiocytoma resembles some forms of human LCH.3,11 Canine reactive histiocytosis, which includes cutaneous and systemic forms, has recently been documented as an angiocentric, pleocellular infiltration of CD1+, CD11c+, Thy-1+, CD4+ activated interstitial dendritic APC, CD8+, TCR {alpha}ß+ T cells, and neutrophils.1 Clinical behavior and response to immunosuppressive therapy are consistent with an immunoregulatory disorder.1

As in humans, localized and disseminated histiocytic sarcomas in dogs can mimic other spindle cell or round cell sarcomas. Accurate diagnosis therefore requires immunophenotypic evaluation of the lesions. Canine localized histiocytic sarcoma presented with a distribution, clinical behavior, and morphologic features that resembled those of previously documented canine malignant fibrous histiocytoma.19,23 The diagnosis of canine malignant fibrous histiocytoma has always been controversial. More recent studies confirmed that this entity likely represents a collection of sarcomas of different cellular origin but with similar histologic features, e.g., fibrosarcomas, leiomyosarcomas, rhabdomyosarcomas, liposarcomas, synovial cell sarcomas, and histiocytic sarcomas.23,56 In a recent study, fibrohistiocytic nodules in the spleen were described.52 Immunhistochemistry was used to document the mesenchymal origin of these nodules. However, the large variation in morphologic features, immunophenotype and clinical behavior of these fibrohistiocytic nodules suggest that these proliferations were of various mesenchymal cell lineages, which likely included soft tissue sarcomas as well as dendritic cell sarcomas. However, a direct comparison of canine splenic dendritic cell sarcomas of this current study with the previously described fibrohistiocytic splenic nodules is not possible because those nodules were not evaluated for expression of leukocyte antigens.52

Because of the diversity of the dendritic APC, the exact dendritic cell sublineage of histiocytic sarcomas has not been determined. Histiocytic sarcomas of nonlymphoid tissues most likely arise from peripheral interstitial dendritic APC, which have been documented in several organ systems.25,27,29 Some dendritic cell sarcomas were characterized by coexpression of Thy-1 (Table 4), a molecule consistently expressed by normal perivascular dermal dendritic APC and by intralesional dendritic cells in canine reactive histiocytosis.1,29,33 However, expression of Thy-1 by interstitial dendritic cells of nonlymphoid tissues often affected by histiocytic sarcoma, such as subcutis and lung, is unknown. Histiocytic sarcomas of lymphoid organs most likely arise from the interdigitating cells within the lymphoid tissue. Interdigitating cells in humans arise from three different subpopulations of dendritic APC.2,34,49 Langerhans cells and interstitial dendritic cells initiate migration after antigen uptake and activation in peripheral tissues and enter the lymph nodes through afferent lymphatics. Human IL-3R{alpha}-rich, CD45RA+, CD4+ dendritic APC enter the lymph organs as undifferentiated cells through the vascular system. Langerhans cells and interstitial dendritic cells have been identified in dogs, but the existence of canine IL-3R{alpha}-rich, CD45RA+, CD4+ dendritic APC cannot be evaluated at this point because appropriate tools to identify canine IL-3R{alpha} expression are not available. However, all tumor samples were consistently negative for CD4, and only a few canine histiocytic sarcomas coexpressed CD45RA.

The prognosis of canine disseminated and localized histiocytic sarcoma of internal organs was poor, but localized histiocytic sarcomas of the subcutis were less devastating. Despite the behavioral differences, no histologic or phenotypic differences were noticed. Early recognition of tumors in clinically easily accessible areas such as the subcutis facilitated timely surgical excision or radiotherapy, which might have decreased the chances of spreading. Disseminated histiocytic sarcomas predominantly affected internal organs, which could explain the delay in their recognition. Most dogs presented with widespread lesions at the time of diagnosis. It remains unknown whether disseminated sarcomas arise as a primary multicentric malignancy, which would justify the use of the term malignant histiocytosis. Alternatively, disseminated histiocytic sarcoma may represent a terminal stage of a localized histiocytic sarcoma of an internal organ with rapid proximal and distant spread.

The majority of canine localized and disseminated histiocytic sarcomas represent aggressive proliferations of myeloid dendritic APC. The broad range of morphologic features observed in these tumors requires immunophenotypic evaluation to confirm the myeloid dendritic cell origin. Given the complexity of dendritic cell differentiation,34,49 additional studies are required to identify the precise origin(s) of the neoplastic myeloid dendritic APC population.


   References
Top
 Abstract
 Material and Methods
 Results
 Discussion
 References
 

  1. Affolter VK, Moore PF: Canine cutaneous and systemic histiocytosis: a reactive histiocytosis of dermal dendritic origin. Am J Dermatopathol 22:40-48, 2000[CrossRef][Medline]
  2. Austyn JM: Dendritic cells in the spleen and lymph node. In: Dendritic Cells; Biology and Clinical Applications, ed. Lotz MT, Thomson AW, pp 179-204, Academic Press, San Diego, CA 1999
  3. Broadbent V, Egeler RM, Nesbit ME Jr: Langerhans cell histiocytosis—clinical and epidemiological aspects. Br J Cancer Suppl 23:11-16, 1994
  4. Bucsky P, Egeler RM: Malignant histiocytic disorders in children. Clinical and therapeutic approaches with a nosologic discussion. Hematol Oncol Clin North Am 12:465-471, 1998[CrossRef][Medline]
  5. Calabi F, Bradbury A: The CD1 system. Tissue Antigens 37:1-9, 1991[Medline]
  6. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261, 1992[CrossRef][Medline]
  7. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 184:695-706, 1996[Abstract/Free Full Text]
  8. Caux C, Vanbervliet B, Massacrier C, Durand I, Banchereau J: Interleukin-3 cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans cells from cord blood CD34+ hematopoietic progenitor cells. Blood 87:2376-2385, 1996[Abstract/Free Full Text]
  9. Cerio R, Griffiths CE, Cooper KD, Nickoloff BJ, Headington JT: Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 121:421-431, 1989[CrossRef][Medline]
  10. Egeler RM, Schmitz L, Sonneveld P, Mannival C, Nesbit ME: Malignant histiocytosis: a reassessment of cases formerly classified as histiocytic neoplasms and review of the literature. Med Pediatr Oncol 25:1-7, 1995[Medline]
  11. Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, Bucsky P, Egeler RM, Elinder G, Gadner H, Gresik M, Henter JI, Imashuku S, Janka-Schaub G, Jaffe R, Ladisch S, Nezelof C, Pritchard J: Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29:157-166, 1997[CrossRef][Medline]
  12. Furue M, Nindl M, Kawabe K, Nakamura K, Ishibashi Y, Sagawa K: Epitope mapping of CD1a, CD1b, and CD1c antigens in human skin: differential localization on Langerhans cells, keratinocytes, and basement membrane zone. J Invest Dermatol 99: (Suppl) 23-26, 1992[CrossRef]
  13. Gadner H: The histiocytic syndromes. In: Dermatology in General Medicine, ed. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, 4th ed., pp 2003-2010, McGraw-Hill, New York, NY 1993
  14. Gleiser CA, Raulston GL, Jardine JH, Gray KN: Malignant fibrous histiocytoma in dogs and cats. Vet Pathol 16:199-208, 1979[Abstract]
  15. Glick AD, Holscher M, Campbell GR: Canine cutaneous histiocytoma: ultrastructural and cytochemical observations. Vet Pathol 13:374-380, 1976[Abstract]
  16. Gogusev J, Nezelof C: Malignant histiocytosis. Histologic, cytochemical, chromosomal, and molecular data with a nosologic discussion. Hematol Oncol Clin North Am 12:445-463, 1998[CrossRef][Medline]
  17. Gross TL, Affolter VK: Advances in skin oncology. In: Advances in Veterinary Dermatology. ed. Kwochka KW, Willemse T, von Tscharner C, pp 382-385, Butterworth-Heinemann, Oxford, UK 1998
  18. Hayden DW, Waters DJ, Burke BA, Manivel JC: Disseminated malignant histiocytosis in a Golden Retriever: clinicopathologic, ultrastructural, and immunohistochemical findings. Vet Pathol 30:256-264, 1993[Abstract]
  19. Hendrick MJ, Brooks JJ, Bruce EH: Six cases of malignant fibrous histiocytoma of the canine spleen. Vet Pathol 29:351-354, 1992[Medline]
  20. Hsu SM, Ho YS, Hsu PL: Lymphomas of true histiocytic origin. Expression of different phenotypes in so-called true histiocytic lymphoma and malignant histiocytosis. Am J of Pathol 138:1389-1404, 1991
  21. Katenkamp D: Morphology and molecular biology of malignant soft tissue sarcomas. Schweiz Rundsch Med Prax 87:1043-1049, 1998[Medline]
  22. Kelly DF: Canine cutaneous histiocytoma. A light and electron microscopic study. Pathol Vet 7:12-27, 1970[Medline]
  23. Kerlin RL, Hendrick MJ: Malignant fibrous histiocytoma and malignant histiocytosis in the dog—convergent or divergent phenotypic differentiation? Vet Pathol 33:713-716, 1996[Abstract]
  24. Laeng H, Gerber H, Mueller J: Malignant histiocytosis (histiocytic sarcoma). A (the?) major cause of the 'midline granuloma syndrome'. Acta Otolaryngol (Stockh) 101:135-145, 1986[Medline]
  25. Maurer D, Stingle G: Dendritic cells in the context of skin immunity. In: Dendritic Cells; Biology and Clinical Applications, ed. Lotz TM, Thomson AW, pp 111-122, Academic Press, San Diego, CA 1999
  26. Mays MB, Bergeron JA: Cutaneous histiocytosis in dogs. J Am Vet Med Assoc 188:377-381, 1986[Medline]
  27. McWilliam AS, Stumbles PA, Holt PG: Dendritic cells in the lung. In: Dendritic Cells; Biology and Clinical Applications, ed. Lotz TM, Thomson AW, pp 123-140, Academic Press, San Diego, CA 1999
  28. Meister P: Malignant fibrous histiocytoma. History, histology, histogenesis. Pathol Res Pract 183:1-7, 1988[Medline]
  29. Meunier L, Gonzalez-Ramos A, Cooper KD: Heterogeneous populations of class II MHC+ cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J Immunol 151:4067-4080, 1993[Abstract]
  30. Moore PF: Systemic histiocytosis of Bernese mountain dogs. Vet Pathol 21:554-563, 1984[Abstract]
  31. Moore PF, Affolter VK, Olivry T, Schrenzel MD: The use of immunological reagents in defining the pathogenesis of canine skin diseases involving proliferation of leukocytes. In: Advances in Veterinary Dermatology. eds. Kwochka KW, Willemse T, von Tscharner C, pp 77-94, Butterworth-Heinemann, Oxford 1998
  32. Moore PF, Rosin A: Malignant histiocytosis of Bernese mountain dogs. Vet Pathol 23:1-10, 1986[Abstract]
  33. Moore PF, Schrenzel MD, Affolter VK, Olivry T, Naydan D: Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin molecules. Am J Pathol 148:1699-1708, 1996[Abstract]
  34. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, Lund-Johansen F: Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 94:12551-12556, 1997[Abstract/Free Full Text]
  35. Peaston AE, Munn RJ, Madewell BR: Clinical vignette. A 7-year-old Bernese Mountain Dog with anemia. J Vet Intern Med 7:101-103, 1993[Medline]
  36. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB: The CD1 family of lipid antigen presenting molecules. Immunol Today 19:362-368, 1998[CrossRef][Medline]
  37. Ramsey IK, McKay JS, Rudorf H, Dobson JM: Malignant histiocytosis in three Bernese Mountain Dogs. Vet Rec 138:440-444, 1996[Abstract/Free Full Text]
  38. Roholl PJ, Kleyne J, Pijpers HW, Van Unnik JA: Comparative immunohistochemical investigation of markers for malignant histiocytes. Hum Pathol 16:763-771, 1985[Medline]
  39. Rosin A, Moore P, Dubielzig R: Malignant histiocytosis in Bernese Mountain Dogs. J Am Vet Med Assoc 188:1041-1045, 1986[Medline]
  40. Saraya K, Reid CD: Synergistic interaction between c-kit ligand (SCF), GM-CSF and TNF promotes optimal dendritic Langerhans cell proliferation from primitive progenitors in human bone marrow. Adv Exp Med Biol 378:13-16, 1995[Medline]
  41. Scherlie PH Jr, Smedes SL, Feltz T, Dougherty SA, Riis RC: Ocular manifestation of systemic histiocytosis in a dog. J Am Vet Med Assoc 201:1229-1232, 1992[Medline]
  42. Schmidt D: Monocyte/macrophage system and malignancies. Med Pediatr Oncol 23:444-451, 1994[Medline]
  43. Schmidt ML, Rutteman GR, van Niel MH, Wolvekamp PT: Clinical and radiographic manifestations of canine malignant histiocytosis. Vet Q 15:117-120, 1993[Medline]
  44. Schmidt ML, Rutteman G, Wolvekamp P: Canine malignant histiocytosis (MH): clinical and radiographic findings. Tijdschr Diergeneeskd 117:(Suppl 1) 43-44, 1992
  45. Schmitz L, Favara BE: Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 12:221-246, 1998[CrossRef][Medline]
  46. Scott DW, Angarano DK, M. SM: Systemic histiocytosis in two dogs. Canine Pract 14:7-12, 1987
  47. Scott DW, Miller WH, Griffin CE: Muller & Kirk's Small Animal Dermatology, 6th ed. pp 1355-1357, WB Saunders, Philadelphia, PA 1995
  48. Shi SR, Chaiwun B, Young L, Cote RJ, Taylor CR: Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J Histochem Cytochem 41:1599-1604, 1993[Abstract]
  49. Shortman K, Caux C: Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 15:409-419, 1997[Abstract/Free Full Text]
  50. Soloeta R, Yanguas I, Saracibar N, Goday JJ: Multiple clustered histiocytofibroma. Apropos of a case with immunohistochemical study. Ann Dermatol Venereol 121:482-484, 1994[Medline]
  51. Soria C, Orradre JL, Garcia-Almagro D, Martinez B, Algara P, Piris MA: True histiocytic lymphoma (monocytic sarcoma). Am J Dermatopathol 14:511-517, 1992[Medline]
  52. Spangler WL, Kass PH: Pathologic and prognostic characteristics of splenomegaly in dogs due to fibrohistiocytic nodules: 98 cases. Vet Pathol 35:488-498, 1998[Abstract]
  53. Stingl G, Bergstresser PR: Dendritic cells: a major story unfolds. Immunol Today 16:330-333, 1995[CrossRef][Medline]
  54. Strobl H, Bello-Fernandez C, Riedl E, Pickl WF, Majdic O, Lyman SD, Knapp W: flt3 Ligand in cooperation with transforming growth factor-beta1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425-1434, 1997[Abstract/Free Full Text]
  55. Strunk D, Rappersberger K, Egger C, Strobl H, Kromer E, Elbe A, Maurer D, Stingl G: Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 87:1292-1302, 1996[Abstract/Free Full Text]
  56. Thoolen RJ, Vos JH, van der Linde-Sipman JS, de Weger RA, van Unnik JA, Misdorp W, van Dijk JE: Malignant fibrous histiocytomas in dogs and cats: an immunohistochemical study. Res Vet Sci 53:198-204, 1992[Medline]
  57. Uno Y, Momoi Y, Watari T, Goitsuka R, Tsujimoto H, Shimada T, Ono K, Goto N, Hasegawa A: Malignant histiocytosis with multiple skin lesions in a dog. J Vet Med Sci 55:1059-1061, 1993[Medline]
  58. Ushigome S, Shimoda T, Nikaido T, Takasaki S: Histopathologic diagnostic and histogenetic problems in malignant soft tissue tumors. Reassessment of malignant fibrous histiocytoma, epithelioid sarcoma, malignant rhabdoid tumor, and neuroectodermal tumor. Acta Pathol Jpn 42:691-706, 1992[Medline]
  59. Vedel J, Vincendeau P, Bezian JH, Taieb A: Flow cytometry analysis of adhesion molecules on human Langerhans cells. Clin Exp Dermatol 17:240-245, 1992[CrossRef][Medline]
  60. Wellman ML, Davenport DJ, Morton D, Jacobs RM: Malignant histiocytosis in four dogs. J Am Vet Med Assoc 187:919-921, 1985[Medline]
  61. Wilson MS, Weiss LM, Gatter KC, Mason DY, Dorfman RF, Warnke RA: Malignant histiocytosis. A reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies. Cancer 66:530-536, 1990[CrossRef][Medline]
Request reprints from Dr. K. Affolter, VM-PMI, School of Veterinary Medicine, University of California, Davis, CA 95616 (USA). E-mail: vkaffolter{at}ucdavis.edu.




This article has been cited by other articles:


Home page
 Vet PatholHome page
G. Avallone, P. Helmbold, M. Caniatti, D. Stefanello, R. C. Nayak, and P. Roccabianca
The Spectrum of Canine Cutaneous Perivascular Wall Tumors: Morphologic, Phenotypic and Clinical Characterization
Vet. Pathol., September 1, 2007; 44(5): 607 - 620.
[Abstract] [Full Text] [PDF]

Home page
 J HeredHome page
J. T. Soller, H. M. Escobar, S. Willenbrock, M. Janssen, N. Eberle, J. Bullerdiek, and I. Nolte
Comparison of the Human and Canine Cytokines IL-1({alpha}/{beta}) and TNF-{alpha} to Orthologous Other Mammalians
J. Hered., August 3, 2007; (2007) esm025v3.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
J. Pinard, C. R. Wagg, C. Girard, M. Kiupel, and C. Bedard
Histiocytic sarcoma in the tarsus of a cat.
Vet. Pathol., November 1, 2006; 43(6): 1014 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
P. F. Moore, V. K. Affolter, and W. Vernau
Canine Hemophagocytic Histiocytic Sarcoma: A Proliferative Disorder of CD11d+ Macrophages.
Vet. Pathol., September 1, 2006; 43(5): 632 - 645.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
V. K. Affolter and P. F. Moore
Feline progressive histiocytosis.
Vet. Pathol., September 1, 2006; 43(5): 646 - 655.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
P. R. Nambiar, S. R. Boutin, R. Raja, and D. W. Rosenberg
Global Gene Expression Profiling: A Complement to Conventional Histopathologic Analysis of Neoplasia
Vet. Pathol., November 1, 2005; 42(6): 735 - 752.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
N. J. Fernandez, K. H. West, M. L. Jackson, and B. A. Kidney
Immunohistochemical and Histochemical Stains for Differentiating Canine Cutaneous Round Cell Tumors
Vet. Pathol., July 1, 2005; 42(4): 437 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. M. Fry, W. Vernau, P. A. Pesavento, C. Bromel, and P. F. Moore
Hepatosplenic Lymphoma in a Dog
Vet. Pathol., September 1, 2003; 40(5): 556 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
M. Lacroix-Triki, L. Lacoste-Collin, S. Jozan, J.-P. Charlet, C. Caratero, and M. Courtade
Histiocytic Sarcoma in C57BL/6J Female Mice is Associated with Liver Hematopoiesis: Review of 41 Cases
Toxicol Pathol, April 1, 2003; 31(3): 304 - 309.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Affolter, V. K.
Right arrow Articles by Moore, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Affolter, V. K.
Right arrow Articles by Moore, P. F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS